Ionis hsd17b13
WebALN-HSD is a subcutaneously administered, investigational RNAi therapeutic targeting HSD17B13 for the treatment of non-alcoholic steatohepatitis (NASH), in collaboration … Web9 apr. 2024 · CARLSBAD, Calif., April 9, 2024/PRNewswire/ -- Ionis Pharmaceuticals, Inc.(NASDAQ: IONS), the leader in antisense therapeutics, today announced that it has …
Ionis hsd17b13
Did you know?
Web7 jan. 2024 · Recently, HSD17B13, a newly identified liver-enriched, hepatocyte-specific, lipid droplet-associated protein, has been reported to be strongly associated with the … WebHSD17B13. 17β-Hydroxysteroid dehydrogenase type 13 also known as 17β-HSD type 13 is an enzyme that in humans is encoded by the HSD17B13 gene. [5] [6] 17β-HSD13 is …
WebA loss-of-function variant in hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) is associated with decreased liver fibrosis, but the underlying mechanisms remain unclear. … WebA common variant in hydroxysteroid 17-beta dehydrogenase 13 ( HSD17B13, rs72613567-A) is associated with a reduced risk of fibrosis in NAFLD, but the underlying mechanism (s) remains unclear. We investigated the effects of this variant in the human liver and in Hsd17b13 knockdown in mice by using a state-of-the-art metabolomics approach.
Web23 sep. 2024 · For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense … Web9 apr. 2024 · AstraZeneca Licenses NASH Drug from Ionis Worth a Potential $330+ Million. Investors in Ionis Pharmaceuticals are happy this morning after the California-based …
Web18 feb. 2024 · Regeneron is now collaborating with Alnylam to advance a small interfering RNA (siRNA) therapeutic targeting HSD17B13 in NASH. Regeneron is also doing its …
Web1 jun. 2024 · Summary. 17β-HSDs are multifunctional enzymes and a large number of 17β-HSD inhibitors have been described in recent years ( Marchais-Oberwinkler et al., 2011 ). Increasing data demonstrate that HSD17B13, as a liver-specific LD protein, plays a critical role in the regulation of hepatic lipid homeostasis. pac wavreWeb1 okt. 2003 · 17-beta-HSD 13 Alternative names Short chain dehydrogenase/reductase family 16C member 3 Short-chain dehydrogenase/reductase 9 Gene names Name HSD17B13 Synonyms SCDR9, SDR16C3 ORF names HMFN0376, UNQ497/PRO1014 Organism names Organism Homo sapiens (Human) Taxonomic identifier 9606 NCBI … pac way hot lunchWeb25 jun. 2024 · MODULATORS OF HSD17B13 EXPRESSION - IONIS PHARMACEUTICALS INC Title: MODULATORS OF HSD17B13 EXPRESSION Document Type and Number: WIPO Patent Application WO/2024/132564 Kind Code: A1 Abstract: Methods, compounds, and compositions useful for inhibiting HSD17B13 expression are … jennifer moore sweatshirts and pantsWeb25 jun. 2024 · MODULATORS OF HSD17B13 EXPRESSION - IONIS PHARMACEUTICALS INC Title: MODULATORS OF HSD17B13 EXPRESSION … jennifer moreno behavioral healthWeb15 jun. 2024 · Hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13), which was newly identified as a liver lipid droplet associated protein, was recently found to be down … pac way elementaryWeb30 jun. 2024 · HSD17B13 is a lipid droplet-associated protein, but its function is still ambiguous. Compared to the other genetic variants that increase risk for FLD, HSD17B13 variants serve a protective role, making this gene a potential therapeutic target. However, the mechanism by which these variants reduce the risk of developing FLD is still unclear. jennifer morey caldwellpac wayne dalton